Prachitee Ayare
Prachitee Ayare has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Madhusudhan Alle
Department of Chemistry, The University of Memphis, Memphis, TN 38152, USA
2 shared publications - Tejaskumar A. Suhagia
University of Memphis
2 shared publications Apurva Bakre
Department of Pharmaceutics Vivekanand Education Society's College of Pharmacy 400074 Mumbai Maharashtra India
1 shared publicationRajashree Hirlkear
Department of Pharmaceutics Vivekanand Education Society's College of Pharmacy 400074 Mumbai Maharashtra India
1 shared publication
Latest Publications
- 26 July 2025
- Published by Springer Nature
- p. 455-483
Biodegradable Beauty: Carbohydrate Polymers in Cosmetics
- 26 July 2025
- Published by Springer Nature
- p. 455-483
Biodegradable Beauty: Carbohydrate Polymers in Cosmetics
- Open Access
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (2) , 433-441
Perspective on Solid Lipid Nanoparticles as Drug Delivery System for Infectious Diseases
Over the years, infectious diseases have significantly contributed to the mortality and morbidity rates in the healthcare system. Conventional treatments have been used for many years to treat infectious diseases, such as oral and topical drug delivery routes. However, these treatments present numerous challenges. The factors such as the solubility of the drug, its size and its molecular weight may affect the efficacy of conventional therapies. Nanotechnology or nanomedicine is one of the novel and promising approaches to overcome these aforementioned challenges for traditional therapies. Solid lipid nanoparticles are a novel approach in the drug delivery system which was first introduced in early 1990s. Their small size, large surface area, high drug loading and the ability to interact with other phases, solid lipid nanoparticles are attractive for improving the performance of pharmaceutical, nutraceutical and other materials. Solid lipid nanoparticles have been proven to be one of the most effective methods of treating infectious diseases (antibiotic-loaded solid lipid nanoparticles). This review emphasizes solid lipid nanoparticles as a delivery system for infectious diseases. Also, it discusses research pertaining to the targeting approach of Solid lipid nanoparticles in infections.
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (2) , 433-441
Open AccessPerspective on Solid Lipid Nanoparticles as Drug Delivery System for Infectious Diseases
Over the years, infectious diseases have significantly contributed to the mortality and morbidity rates in the healthcare system. Conventional treatments have been used for many years to treat infectious diseases, such as oral and topical drug delivery routes. However, these treatments present numerous challenges. The factors such as the solubility of the drug, its size and its molecular weight may affect the efficacy of conventional therapies. Nanotechnology or nanomedicine is one of the novel and promising approaches to overcome these aforementioned challenges for traditional therapies. Solid lipid nanoparticles are a novel approach in the drug delivery system which was first introduced in early 1990s. Their small size, large surface area, high drug loading and the ability to interact with other phases, solid lipid nanoparticles are attractive for improving the performance of pharmaceutical, nutraceutical and other materials. Solid lipid nanoparticles have been proven to be one of the most effective methods of treating infectious diseases (antibiotic-loaded solid lipid nanoparticles). This review emphasizes solid lipid nanoparticles as a delivery system for infectious diseases. Also, it discusses research pertaining to the targeting approach of Solid lipid nanoparticles in infections.